News
NGEN
1.760
0.00%
0.000
NervGen Pharma Posts Larger Q2 2026 Loss but Strengthens Cash Position
TipRanks · 16h ago
NervGen Pharma GAAP EPS of -C$0.37
Seeking Alpha · 17h ago
*NervGen Pharma 2Q Loss/Shr C$0.32 >NGEN
Dow Jones · 17h ago
Weekly Report: what happened at NGEN last week (0803-0807)?
Weekly Report · 3d ago
Weekly Report: what happened at NGEN last week (0727-0731)?
Weekly Report · 08/03 09:05
Weekly Report: what happened at NGEN last week (0720-0724)?
Weekly Report · 07/27 09:05
Weekly Report: what happened at NGEN last week (0713-0717)?
Weekly Report · 07/20 09:05
Micron To Rally Around 87%? Here Are 10 Top Analyst Forecasts For Tuesday
Benzinga · 07/14 12:19
NervGen Pharma Price Target Cut to $15.00/Share From $18.00 by HC Wainwright & Co.
Dow Jones · 07/14 10:28
NervGen Pharma Is Maintained at Buy by HC Wainwright & Co.
Dow Jones · 07/14 10:28
HC Wainwright & Co. Maintains Buy on NervGen Pharma, Lowers Price Target to $15
Benzinga · 07/14 10:19
NervGen Pharma price target lowered to $15 from $18 at H.C. Wainwright
TipRanks · 07/14 10:00
NervGen Pharma Price Target Announced at $10.00/Share by Leerink Partners
Dow Jones · 07/13 18:09
NervGen Pharma initiated with an Outperform at Leerink
TipRanks · 07/13 11:45
Weekly Report: what happened at NGEN last week (0706-0710)?
Weekly Report · 07/13 09:05
United Therapeutics Vs. Regencell Bioscience: I Choose Profits Over Promises
Seeking Alpha · 07/06 12:45
Weekly Report: what happened at NGEN last week (0629-0703)?
Weekly Report · 07/06 09:05
NervGen Pharma Sets Up US$50 Million ATM Equity Program With Leerink Partners
TipRanks · 07/02 21:47
NervGen Pharma: I Think The Biggest Risks Are Now Behind It
Seeking Alpha · 07/02 16:25
Weekly Report: what happened at NGEN last week (0622-0626)?
Weekly Report · 06/29 09:05
More
Webull provides a variety of real-time NGEN stock news. You can receive the latest news about Nervgen Pharma Corp through multiple platforms. This information may help you make smarter investment decisions.
About NGEN
NervGen Pharma Corp. is a clinical-stage biotech company. The Company is engaged in developing treatments to promote nervous system repair in the settings of neurotrauma and neurologic disease. NVG-291 is in a Phase 1b/2a clinical trial in spinal cord injury and has undertaken preclinical evaluation of a new development candidate, NVG-300, in models of ischemic stroke, amyotrophic lateral sclerosis (ALS) and spinal cord injury (SCI). Its NVG-291 is a therapeutic peptide targeting nervous system repair.